ClinicalTrials.gg
Active, not recruitingNCT07938099Updated Nov 16, 2026

Real-World Study Comparing PCSK9 Monoclonal Antibody With Cholesterol Absorption Inhibitors in Patients With ASCVD for Secondary Prevention

An observational study in Hyperlipidemia, sponsored by Xin Li. Active, not recruiting at 1 site in China. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Xin Li · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
42,088
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 94 studies in Hyperlipidemias with a site in China — 30 open to participants now, 37 under way, 7 of them phase 3. Hyperlipidemias · China.

Enrollment
2nd of 16
42,088 · median 1,151
Started
2026
with 13 others
Observational
16 of 94
8 open now
Primary completion
2026-12
later than 16 of 36 live
Registered
94th of 94
by date

Among the 94 studies in Hyperlipidemias with a site in China, this one is the 2nd largest by enrollment of the 16 observational ones that give a count, is one of 14 that started in 2026, is one of 16 observational ones, reaches primary completion later than 16 of the 36 other live ones, and was the 94th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

30 of the 94 studies in Hyperlipidemias with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Hyperlipidemias with a site in China, or all of them as a file.
02

Study summary

This study is a retrospective non-interventional cohort study, utilizing real-world administrative claim data and electronic health record data associated with the medical insurance database in Nanjing, China (2019-2026). The study aims to evaluate the real-world effectiveness and cost-effectiveness of PCSK9 monoclonal antibody(evolocumab, alirocumab, tafolecimab, ongericimab, recaticimab and ebronucimab) versus cholesterol absorption inhibitors (ezetimibe and hyzetimibe) as add-on lipid-lowering therapy in adults undergoing secondary prevention of atherosclerotic cardiovascular diseases (ASCVD). Outcomes include composite CVD, three-point major adverse cardiovascular events (MACE), fatal CVD, all-cause mortality, discontinuation, and persistence. Direct medical costs will be estimated from third-party payer and healthcare system perspectives. Cost-effectiveness will be expressed in terms of the incremental cost per prevented MACE), the number needed to treat (NNT), and the incremental cost per prevented all-cause death. Sensitivity analyses will assess robustness. Findings are intended to inform clinical selection, reimbursement, and dynamic adjustment of the medical insurance directory for ASCVD secondary prevention.

Read the detailed description

Patients with ASCVD remain at high risk of recurrent cardiovascular events despite statin therapy(lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin and pitavastatin). Guidelines recommend intensifying lipid-lowering treatment with add-on agents such as PCSK9 monoclonal antibody or cholesterol absorption inhibitors when LDL-C goals are not achieved. PCSK9 monoclonal antibody produce large LDL-C reductions and have proven cardiovascular benefit in outcome trials, but their acquisition costs are substantially higher than those of ezetimibe. In Chinese real-world practice, treatment choice is influenced not only by efficacy and safety but also by affordability, reimbursement, adherence, and supply continuity. However, real-world comparative effectiveness and cost-effectiveness evidence directly comparing PCSK9i with CAIs in ASCVD secondary prevention remains limited. This study will use routinely collected data to complement trial-based evidence and support payer and clinical decision-making.

This retrospective cohort study will use de-identified linked data from regional medical insurance claims, electronic medical records, and death registry records in Nanjing, China, covering 1 Jan 2019 to 31 Aug 2026. As of the end of 2025, 8,960,800 people were enrolled in Nanjing's basic medical insurance program.

This study identified patients diagnosed between 2020 and August 31, 2026, with pure hypercholesterolemia, mixed hyperlipidemia, other hyperlipidemias, unstable angina, acute myocardial infarction, old myocardial infarction, other acute ischemic heart diseases, atherosclerotic heart disease, coronary artery aneurysms and coronary artery dissections, cerebral infarction, cerebral stroke (not specifically classified as hemorrhagic or ischemic), occlusion and stenosis of the pre-cerebral arteries, occlusion and stenosis of the cerebral arteries, atherosclerosis, and other peripheral vascular diseases.

This study will compare two treatment strategies: initiation of a PCSK9 monoclonal antibody versus initiation of a cholesterol absorption inhibitor, both in the context of combination statin therapy and without prior use of the other of these drugs. The index dates used in the baseline case-control analysis and sensitivity analysis are defined as the time when a patient began continuous treatment with a PCSK9 monoclonal antibody or a cholesterol absorption inhibitor, and the time when a patient first discontinued continuous treatment with a PCSK9 monoclonal antibody or a cholesterol absorption inhibitor, respectively. These two definitions of index dates are used to address study uncertainties that may arise from potential bias. Eligible patients were adults aged 40-85 years with secondary prevention for ASCVD (i.e., a history of myocardial infarction, stroke, or symptomatic peripheral arterial disease). Patients who used PCSK9 monoclonal antibody or cholesterol absorption inhibitors consistently during this period were further identified. Consistent users were defined as patients who received a monthly refill of their medication for three consecutive months; in the PCSK9 monoclonal antibody group, this referred to refills of PCSK9 monoclonal antibody and statins, while in the cholesterol absorption inhibitor group, it referred to refills of cholesterol absorption inhibitors and statins. Stable users in both groups may have had multiple stable treatment regimens with the drug over time (in chronological order). Patients were followed up from the index date until death, loss to follow-up, occurrence of MACE, or August 31, 2026, whichever occurred first.

Direct medical costs will be measured from two perspectives: (1) third-party payer perspective, including reimbursed inpatient, outpatient, emergency, pharmacy, and procedure costs; and (2) healthcare system perspective, adding patient out-of-pocket payments. Costs will be adjusted for baseline healthcare expenditure and standardized to 2026 Chinese yuan. Effectiveness will be summarized using number NNT to prevent one MACE or one death. Incremental cost-effectiveness ratios (ICERs) will be calculated as the incremental adjusted cost per MACE avoided and, where feasible, as the incremental adjusted cost per QALY, using a Markov model based on real-world transition probabilities and published utility values. Results will be reported following the CHEERS 2022 checklist. The study is observational and non-interventional; no treatment will be assigned, and all analyses will use de-identified data with ethics approval.

03

Conditions studied

  • Hyperlipidemia

Browse trials for

Keywords

  • PCSK9 Inhibitors
  • Cholesterol Absorption Inhibitors
  • Cost-effectiveness
  • Major adverse cardiovascular events
  • Real-world evidence
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study participants will be selected from de-identified, linked regional health insurance reimbursement data, electronic health records, and death registration data from the Nanjing area of China, covering the time period from January 1, 2019, to August 31, 2026. The final cohort will be confirmed based on factors such as age, disease diagnosis, and history of medication exposure. Patient survival status information will be linked to the Bureau of Civil Affairs' resident death registration database. The source population includes approximately 8,960,800 people enrolled in Nanjing's basic medical insurance program as of the end of 2025. The study population will consist of adults aged 40-85 years with ASCVD receiving secondary prevention who newly initiated either a PCSK9 monoclonal antibody or a cholesterol absorption inhibitor while on statin therapy and without prior use of the other of these drugs, and who met the consistent-user definition.

Eligibility criteria

Adults aged 40-85 years who were diagnosed between 2020 and 31 August 2026 with pure hypercholesterolemia, mixed hyperlipidemia, other hyperlipidemias, or the specified ASCVD conditions (including unstable angina, acute myocardial infarction, old myocardial infarction, other acute ischemic heart disease, atherosclerotic heart disease, coronary artery aneurysm/dissection, cerebral infarction, stroke not specifically classified as hemorrhagic or ischemic, pre-cerebral/cerebral artery occlusion and stenosis, atherosclerosis, and other peripheral vascular diseases), and who were receiving secondary prevention for ASCVD (i.e., a history of myocardial infarction, stroke, or symptomatic peripheral arterial disease), will be included. The age restriction of 40 to 85 years is intended to exclude patients with congenital, early-onset hypercholesterolemia-such as primary hypercholesterolemia and homozygous familial hypercholesterolemia-for whom secondary prevention is difficult. Eligible patients must have newly initiated a PCSK9 monoclonal antibody or a cholesterol absorption inhibitor while receiving combination statin therapy, without prior use of the other of these drugs. The index dates used in the baseline case-control analysis and sensitivity analysis are defined as the time when a patient began continuous treatment with a PCSK9 monoclonal antibody or a cholesterol absorption inhibitor, and the time when a patient first discontinued continuous treatment with a PCSK9 monoclonal antibody or a cholesterol absorption inhibitor, respectively. Patients must be consistent users, defined as receiving a monthly refill for three consecutive months (PCSK9 monoclonal antibody plus statin in the PCSK9 monoclonal antibody group, or cholesterol absorption inhibitor plus statin in the cholesterol absorption inhibitor group).

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
42,088 participants (actual)
Patient registry
No

Groups and cohorts

  • PCSK9 monoclonal antibody plus statins

    PCSK9 monoclonal antibodies include evolocumab, alirocumab, t

  • Cholesterol absorption inhibitors combined with statins

    Cholesterol absorption inhibitors included ezetimibe and hyzetimibe, and statins included lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin, and pitavastatin. Exposure was identified through medical insurance reimbursement claims.

06

What researchers measure

Primary outcomes

  1. Major adverse cardiovascular events (MACE)

    MACE includes myocardial infarction, stroke, recurrent angina pectoris, revascularization surgery, heart failure, severe arrhythmia, etc.

    Time frame: Patients were followed up from the index date until death, loss to follow-up, or August 31, 2026, whichever occurred first.

  2. All-cause mortality

    All-cause mortality refers to the total number of deaths caused by various factors within a certain period.

    Time frame: Patients were followed up from the index date until death, loss to follow-up, or August 31, 2026, whichever occurred first.

07

Study locations

1 site
08

References and documents

Publications

  • Khera R, Aminorroaya A, Dhingra LS, Thangaraj PM, Pedroso Camargos A, Bu F, Ding X, Nishimura A, Anand TV, Arshad F, Blacketer C, Chai Y, Chattopadhyay S, Cook M, Dorr DA, Duarte-Salles T, DuVall SL, Falconer T, French TE, Hanchrow EE, Kaur G, Lau WCY, Li J, Li K, Liu Y, Lu Y, Man KKC, Matheny ME, Mathioudakis N, McLeggon JA, McLemore MF, Minty E, Morales DR, Nagy P, Ostropolets A, Pistillo A, Phan TP, Pratt N, Reyes C, Richter L, Ross JS, Ruan E, Seager SL, Simon KR, Viernes B, Yang J, Yin C, You SC, Zhou JJ, Ryan PB, Schuemie MJ, Krumholz HM, Hripcsak G, Suchard MA. Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM. J Am Coll Cardiol. 2024 Sep 3;84(10):904-917. doi: 10.1016/j.jacc.2024.05.069. PubMed 39197980 ↗
  • Zehra A, Deng Y, Swarna KS, Herrin J, Polley EC, Neumiller JJ, Galindo RJ, Umpierrez GE, Ross JS, Brito JP, Montori VM, Borah BJ, Maron BA, Mickelson MM, McCoy RG. Comparative Effectiveness of Individual Sodium Glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: Emulation of a Target Trial. J Am Heart Assoc. 2026 May 19;15(10):e046238. doi: 10.1161/JAHA.125.046238. Epub 2026 May 14. PubMed 42132163 ↗
  • Yang CY, Chen YR, Ou HT, Kuo S. Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review. Cardiovasc Diabetol. 2021 Jan 19;20(1):21. doi: 10.1186/s12933-020-01211-4. PubMed 33468131 ↗

Individual participant data

Plan to share: No — IPD will not be shared because the ethics committee approval and informed consent obtained for this retrospective study do not include permission for secondary data sharing with third parties.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartActual
Aug 24, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938099
Lead sponsor
Xin Li
Responsible party
Xin Li (Professor, PhD, PhD supervisor, Deputy Dean of the School of Pharmacy, Nanjing Medical University, Nanjing Medical University) — Sponsor-investigator
First posted
Nov 16, 2026
Start date
Aug 24, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion